Species differences in metabolism of a new antiepileptic drug candidate, DSP-0565 [2-(2'-fluoro[1,1'-biphenyl]-2-yl)acetamide].
Acetamides
/ blood
Administration, Oral
Adolescent
Adult
Animals
Anticonvulsants
/ blood
Biphenyl Compounds
Dogs
Feces
/ chemistry
Female
Hepatocytes
/ metabolism
Humans
Hydrolysis
Male
Middle Aged
Models, Biological
Oxidation-Reduction
Rats, Sprague-Dawley
Single-Blind Method
Species Specificity
Young Adult
DSP-0565
hepatocytes
metabolic pathway
metabolism
pharmacokinetics
Journal
Biopharmaceutics & drug disposition
ISSN: 1099-081X
Titre abrégé: Biopharm Drug Dispos
Pays: England
ID NLM: 7911226
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
29
10
2018
revised:
06
03
2019
accepted:
21
03
2019
pubmed:
30
3
2019
medline:
22
1
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
The metabolism and pharmacokinetics of DSP-0565 [2-(2'-fluoro[1,1'-biphenyl]-2-yl)acetamide], an antiepileptic drug candidate, was investigated in rats, dogs, and humans. In human hepatocytes, [
Substances chimiques
2-(2'-fluoro-(1,1'-biphenyl)-2-yl)acetamide
0
Acetamides
0
Anticonvulsants
0
Biphenyl Compounds
0
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
165-175Informations de copyright
© 2019 John Wiley & Sons, Ltd.